RevealDx is highlighting U.K. research investigating its CADx AI software for lung nodule risk stratification.
The firm's RevealAI-Lung characterizes nodules by producing a score called the Malignancy Similarity Index (mSI) and may be useful for managing incidental lung nodules. The product is intended for use in markets with EU MDR compliance.
A retrospective validation study in partnership with the Royal United Hospitals Bath NHS Trust reported that mSI "significantly improved nodule classification in incidental lung nodules when combined with current best practice [British Thoracic Society] BTS guidelines," according to the firm. In particular, the paper pointed out that the mSI reduces ambiguity with intermediate-sized (8 mm-15 mm) nodules.
As part of the announcement, RevealDx also noted a previously announced integration with Riverain and a partnership with Sirona Medical.
